Robert Moscato Jr. compensation by year
Avalo Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2017 | FY2018 |
|---|---|---|
| Salary | $25,000 | $70,685 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $0 | $0 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $200,000 |
| Total | $25,000 | $270,685 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed June 19, 2019, accession 0001628280-19-008116, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001628280-19-008116. Every figure is read from that document and cited to the page and table it appears in. Filed June 19, 2019.
Avalo Therapeutics’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Peter Greenleaf | Former Chief Executive Officer | $5,090,787 |
| Mariam Morris | Former Chief Financial Officer | $687,468 |
| Joseph Miller | Chief Financial Officer, Principal Executive Officer and Principal Financial Officer | $672,985 |
| James Harrell Jr. | Executive Vice President, Marketing and External Communications | $621,500 |
| Pericles Calias | Former Chief Scientific Officer | $351,305 |
| Robert Moscato Jr. · this page | Former President, Chief Operating Officer and Director | $270,685 |
| Simon Pedder | Former Executive Chairman of the Board | $27,644 |
The full Avalo Therapeutics compensation record
free company briefThis page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.